PITTSBURGH, April 24, 2025–(BUSINESS WIRE)–CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, core cohort dose-limiting toxicity observation…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company developing a safe and effective preventative treatment for cytokine release syndrome (CRS) and the neurotoxicity immune effector cell-associated neurotoxicity syndrome (ICANS), announced today that it has been awarded…
PITTSBURGH, April 24, 2025–(BUSINESS WIRE)–CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, core cohort dose-limiting toxicity observation…
The Pittsburgh Technology Council’s Tech 50 Awards honors technology innovation in our region. On Thursday, November 14, 2024, we will celebrate the most successful and innovative companies in Southwestern Pennsylvania at the 28th annual Tech…